US › Healthcare

Zura Bio Limited Class A Ordinary Shares (ZURA)

US · Healthcare · Biotechnology

$5.69+3.08%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-24.2M
Profit YoY
-38.9%
EPS
$-0.22
EPS estimate
$-0.18

EPS came in at -0.22 against a street estimate of -0.18 — a miss of 22.2%.

Key statistics

Market cap
$515.2M
Forward P/E
0.0
P/B
2.38
Book value
$2.28
EPS (TTM)
$-1.09
52-week high
$7.44
52-week low
$1.39
50-day MA
$4.66
200-day MA
$4.98
Beta
-0.04

Analyst view

Analysts rate Zura Bio Limited Class A Ordinary Shares a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $15.67.

Shareholding

Insiders
21.51%
Institutions
79.09%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.54%
VR Adviser, LLC6.77%
JPMorgan Chase & Co4.69%
Great Point Partners LLC4.44%
BRAIDWELL LP4.20%
Siren, L.L.C.3.93%
COMMODORE CAPITAL LP3.42%
Pfizer Inc2.99%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Zura Bio Limited Class A Ordinary Shares — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.